India is proceeding with its plan to reform how sponsors and CROs pay compensation to patients, but the draft guidance contains some confusing wording that has troubled the industry. As Outsourcing-Pharma reports, the proposed guidelines say trial runners must pay patients if the tested drug fails "to provide intended therapeutic effect," which the industry points out goes against the very purpose of conducting a clinical trial. Some in the CRO business believe the government will eventually amend the language, but the process could take time. Report